BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 15051759)

  • 1. Cell surface organization of stress-inducible proteins ULBP and MICA that stimulate human NK cells and T cells via NKG2D.
    Eleme K; Taner SB; Onfelt B; Collinson LM; McCann FE; Chalupny NJ; Cosman D; Hopkins C; Magee AI; Davis DM
    J Exp Med; 2004 Apr; 199(7):1005-10. PubMed ID: 15051759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
    Song H; Kim J; Cosman D; Choi I
    Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
    Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
    Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
    Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
    Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.
    Raffaghello L; Prigione I; Airoldi I; Camoriano M; Levreri I; Gambini C; Pende D; Steinle A; Ferrone S; Pistoia V
    Neoplasia; 2004; 6(5):558-68. PubMed ID: 15548365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
    Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR
    Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein.
    Welte SA; Sinzger C; Lutz SZ; Singh-Jasuja H; Sampaio KL; Eknigk U; Rammensee HG; Steinle A
    Eur J Immunol; 2003 Jan; 33(1):194-203. PubMed ID: 12594848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of natural killer (NK) cell cytotoxicity by fever-range thermal stress is dependent on NKG2D function and is associated with plasma membrane NKG2D clustering and increased expression of MICA on target cells.
    Ostberg JR; Dayanc BE; Yuan M; Oflazoglu E; Repasky EA
    J Leukoc Biol; 2007 Nov; 82(5):1322-31. PubMed ID: 17711975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteolytic release of soluble UL16-binding protein 2 from tumor cells.
    Waldhauer I; Steinle A
    Cancer Res; 2006 Mar; 66(5):2520-6. PubMed ID: 16510567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein.
    Rölle A; Mousavi-Jazi M; Eriksson M; Odeberg J; Söderberg-Nauclér C; Cosman D; Kärre K; Cerboni C
    J Immunol; 2003 Jul; 171(2):902-8. PubMed ID: 12847260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the NKG2D ligand UL16 binding protein-1 (ULBP-1) on dendritic cells.
    Schrama D; Terheyden P; Otto K; Kämmerer U; Bröcker EB; Lühder F; Cosman D; Andersen MH; Becker JC
    Eur J Immunol; 2006 Jan; 36(1):65-72. PubMed ID: 16342232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The inhibitory effects of synthetic short peptides, mimicking MICA and targeting at NKG2D receptors, on function of NK cells.
    Zhang B; Wei H; Zheng X; Zhang J; Sun R; Tian Z
    Peptides; 2005 Mar; 26(3):405-12. PubMed ID: 15652646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells.
    Sutherland CL; Chalupny NJ; Schooley K; VandenBos T; Kubin M; Cosman D
    J Immunol; 2002 Jan; 168(2):671-9. PubMed ID: 11777960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four novel ULBP splice variants are ligands for human NKG2D.
    Cao W; Xi X; Wang Z; Dong L; Hao Z; Cui L; Ma C; He W
    Int Immunol; 2008 Aug; 20(8):981-91. PubMed ID: 18544572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of NKG2D ligands on human dendritic cells by TLR ligand stimulation and RNA virus infection.
    Ebihara T; Masuda H; Akazawa T; Shingai M; Kikuta H; Ariga T; Matsumoto M; Seya T
    Int Immunol; 2007 Oct; 19(10):1145-55. PubMed ID: 17878262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UL16 binding proteins.
    Cao W; He W
    Immunobiology; 2004; 209(3):283-90. PubMed ID: 15518340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression of NKG2D ligands in multidrug-resistant nasopharyngeal carcinoma cell line CNE2/DDP and their effects on cytotoxicity of natural killer cells].
    Mei JZ; Guo KY; Wei HM; Song CY
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jun; 27(6):887-9. PubMed ID: 17584663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of NKG2D ligands on dendritic cells at different development stages and its effect on cytotoxicity of NK cells].
    Tu SF; Guo KY; Hu LS; Mei JZ; Zhou J; Sun M
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Apr; 24(4):341-3, 347. PubMed ID: 18394338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor.
    Cosman D; Müllberg J; Sutherland CL; Chin W; Armitage R; Fanslow W; Kubin M; Chalupny NJ
    Immunity; 2001 Feb; 14(2):123-33. PubMed ID: 11239445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MICA/NKG2D-mediated immunogene therapy of experimental gliomas.
    Friese MA; Platten M; Lutz SZ; Naumann U; Aulwurm S; Bischof F; Bühring HJ; Dichgans J; Rammensee HG; Steinle A; Weller M
    Cancer Res; 2003 Dec; 63(24):8996-9006. PubMed ID: 14695218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.